Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia
Conditions
Interventions
Dalbavancin
Linezolid
+2 more
Locations
1
United States
Mercury Street Medical Group
Butte, Montana, United States
Start Date
November 1, 2015
Primary Completion Date
November 1, 2016
Completion Date
December 1, 2016
Last Updated
January 22, 2016
NCT07425561
NCT07109310
NCT06710080
NCT06210282
NCT02559310
NCT02922387
Lead Sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions